Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to doravirine/islatravir vs continued bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-1
jRCT2051230003Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of doravirine + islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, Percentage of participants who experience adverse events through Week 48 and 1 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
doravirine + islatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2051230003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230003.